Received Mar 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | Unknown | — |
The patient forgot to take final dose of Vivotif and could not take additionally because of traveling out of country; Case reference number US-BN-2024-000162 is a spontaneous case report initially received from other health care professional via Med Communications (reference number: USBAV24-0278) on 07-Feb-2024 and concerns 56-years-old male patient. The patient's medical history and concomitant medications were not provided. On unspecified dates, the patient received the first, the second and third dose of Vivotif (batch number: unknown) at an unknown dose and route of administration, for immunization against disease caused by Salmonella typhi. As reported, the patient forgot to take final dose of Vivotif and was travelling out of country and did not have pills. The patient would not be able to return home until 24th February and then will immediately depart for another country on the 27th (explicitly coded as 'incomplete course of vaccination'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif vaccine. No further information was provided.; Reporter's Comments: A 56-year-old male patient forgot to take the final dose of Vivotif for immunization against disease caused by Salmonella typhi after the patient received the first, the second and third dose of Vivotif, which is considered as incomplete course of vaccination. It was unknown if the patient experienced any adverse event due to Vivotif vaccine. Incomplete course of vaccination is considered as listed per company convention. The patient's medical history and concomitant medications were not provided. Incomplete course of vaccination has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A 56-year-old male patient forgot to take the final dose of Vivotif for immunization against disease caused by Salmonella typhi after the patient received the first, the second and third dose of Vivotif, which is considered as incomplete course of vaccination. It was unknown if the patient experienced any adverse event due to Vivotif vaccine. Incomplete course of vaccination is considered as listed per company convention. The patient's medical history and concomitant medications were not provided. Incomplete course of vaccination has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None